Yu Jingao, Zhang Dongbo, Liang Yanni, Zhang Zhen, Guo Jianming, Chen Yanyan, Yan Yafeng, Liu Hongbo, Lei Liyan, Wang Zheng, Tang Zhishu, Tang Yuping, Duan Jin-Ao
Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization, State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), Shaanxi Innovative Drug Research Center, The Youth Innovation Team of Shaanxi Universities, Shaanxi University of Chinese Medicine, Xianyang, China.
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing, China.
Front Pharmacol. 2020 Jul 16;11:869. doi: 10.3389/fphar.2020.00869. eCollection 2020.
In traditional Chinese Medicine (TCM), the licorice-yuanhua herbal pair is one of the most representative incompatible herbal pairs recorded in the "eighteen incompatible herbal pairs" theory. Previous studies of our research group have demonstrated several gut-related side-effects induced by the licorice-yuanhua herbal pair. In this study, we investigated whether and why this incompatible herbal pair could induce gut tissue damage. After licorice-yuanhua treatment, the duodenum, ileum, and colon and serum biomarkers of mice were examined by pathological staining, Western blot, and ELISA assays. The IEC-6 cells and LS174T cells were treated with licorice saponins, yuanhua flavonoids, and di-terpenes; iTRAQ-labeled proteomic technology was then used to explore their synergistic effects on mucosa cells, followed by verification of ZO-1 and MUC-2 protein expressions. The results showed that the licorice-yuanhua herbal pair induced ileum tissue injuries, including epithelial integrity loss, inflammation, and edema. These injuries were verified to be related to epithelial and mucous barrier weakening, such as downregulated ileum ZO-1 and MUC-2 protein expressions. Proteomic analysis also suggested that glycyrrhizic acid and genkwanin synergistically influence tight junction pathways in LS174T cells. Furthermore, licorice saponins, yuanhua flavonoids, and di-terpenes dose/structure-dependently downregulate ZO-1 and MUC-2 protein expressions in mucosa cells. Our study provides different insights into the incompatibility mechanisms and material basis of the licorice-yuanhua herbal pair, especially that besides toxic di-terpenes, licorice saponins and yuanhua flavonoids, which are commonly known to be non-toxic compounds, can also take part in the gut damage induced by the licorice-yuanhua herbal pair.
在传统中医(TCM)中,甘草-芫花药对是“十八反”理论中记载的最具代表性的相反药对之一。我们研究小组之前的研究已经证明了甘草-芫花药对会引发几种与肠道相关的副作用。在本研究中,我们调查了这种相反药对是否以及为何会导致肠道组织损伤。在给予甘草-芫花处理后,通过病理染色、蛋白质印迹法和酶联免疫吸附测定法检测小鼠的十二指肠、回肠、结肠及血清生物标志物。用甘草皂苷、芫花黄酮和二萜类化合物处理IEC-6细胞和LS174T细胞;然后使用iTRAQ标记的蛋白质组学技术来探究它们对黏膜细胞的协同作用,随后验证紧密连接蛋白1(ZO-1)和黏蛋白2(MUC-2)的蛋白表达。结果表明,甘草-芫花药对会导致回肠组织损伤,包括上皮完整性丧失、炎症和水肿。这些损伤被证实与上皮和黏液屏障减弱有关,如回肠中ZO-1和MUC-2蛋白表达下调。蛋白质组学分析还表明,甘草酸和芫花素对LS174T细胞中的紧密连接通路有协同影响。此外,甘草皂苷、芫花黄酮和二萜类化合物在黏膜细胞中呈剂量/结构依赖性下调ZO-1和MUC-2蛋白表达。我们的研究为甘草-芫花药对的配伍禁忌机制和物质基础提供了不同的见解,特别是除了有毒的二萜类化合物外,通常被认为无毒的甘草皂苷和芫花黄酮也可参与甘草-芫花药对引起的肠道损伤。